Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab after Radioembolization for MSS Colorectal Cancer Liver Metastases
NCT03005002Phase 1Completed
- Sponsor
- City of Hope
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in colorectal cancer (metastatic) (mCRC) and liver metastases, sponsored by City of Hope. Started Jun 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (metastatic) (mCRC)liver metastases
Beyond the preview
Go deeper on NCT03005002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005002.